Diabetes therapy--focus on Asia: second-line therapy debate: insulin/secretagoguesRoy Eldor
Division of Diabetes and The Endocrinology Service, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Diabetes Metab Res Rev 28:85-9. 2012
..It is important to emphasize that regardless of it being a review of published evidence, it primarily represents the professional opinion of the writers...
Innovative immune-based therapeutic approaches for the treatment of type 1 diabetes mellitusRoy Eldor
Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel
Int Rev Immunol 24:327-39. 2005
..Here we review the most promising therapies developed based on these targets and emphasize those that have reached human phase clinical investigation...
- Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results
Roy Eldor
Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
Diabetes Metab Res Rev 25:316-20. 2009
....
- Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour
Roy Eldor
Endocrinology and Metabolism Service, Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Clin Endocrinol (Oxf) 74:593-8. 2011
..Glucagonoma is a pancreatic neuroendocrine tumour that arises from alpha cells in the pancreas and is often accompanied by a characteristic clinical syndrome...
Inhibition of nuclear factor-κB activation in pancreatic β-cells has a protective effect on allogeneic pancreatic islet graft survivalRoy Eldor
Department of Endocrinology, Hadassah University Hospital, Jerusalem, Israel
PLoS ONE 8:e56924. 2013
..Furthermore, we suggest a potential, readily available therapeutic agent that may temper this process...
- Immune modulation for prevention of type 1 diabetes mellitus
Itamar Raz
Diabetes Research Center, Department of Medicine, Hadassah-Hebrew University Hospital, Jerusalem 91120, Israel
Trends Biotechnol 23:128-34. 2005
..Here, we review the results of these trials...
- Novel glucagon-like peptide-1 analog delivered orally reduces postprandial glucose excursions in porcine and canine models
Roy Eldor
Diabetes Unit, Hadassah Hebrew University Medical Center, Jerusalem, Israel
J Diabetes Sci Technol 4:1516-23. 2010
..To date, GLP-1 analogs are only available as injectable dosage forms, and its oral delivery is expected to provide physiological portal/peripheral concentration ratios while fostering patient compliance and adherence...
- Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study
Roy Eldor
Diabetes Unit, Internal Medicine, Hadassah University Hospital, Jerusalem, Israel
PLoS ONE 8:e59524. 2013
..In conclusion, ORMD-0801 oral insulin capsules in conjunction with subcutaneous insulin injections, well tolerated and effectively reduced glycemia throughout the day. TRIAL REGISTRATION: Clinicaltrials.gov NCT00867594...
- Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms
Itamar Raz
Diabetes Unit, Hadassah University Hospital, Jerusalem, Israel
Diabetes Metab Res Rev 28:321-4. 2012
..Adherence to strict scientific methodology, ongoing large clinical trials and creating adjudicated patient databases may facilitate early recognition of adverse effects while avoiding disruptive false alarms...
- Early use of insulin in type 2 diabetes
Roy Eldor
Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
Diabetes Res Clin Pract 68:S30-5. 2005
..This new approach, its rationale, benefits and misgivings are discussed in this review...
- Effect of short-term hyperglycemia on protein kinase C alpha activation in human erythrocytes
Leonid Livshits
The Diabetes Research Center, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Rev Diabet Stud 9:94-103. 2012
..Protein kinase C alpha (PKCα) is a major regulator of many metabolic processes and structural changes in erythrocytes, and may play a significant role in the development of hyperglycemia-mediated cellular abnormalities...
- The ToI-beta transgenic mouse: a model to study the specific role of NF-kappaB in beta-cells
Roy Eldor
Department of Endocrinology, Hadassah University Hospital, Jerusalem, Israel
Diabetes Res Clin Pract 86:S7-14. 2009
..Together, our results show the ToI-beta mouse model to be a highly controlled and very accurate model for examining pancreatic beta-cell-specific temporal inhibition of NF-kappaB...
- The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain
Roy Eldor
Diabetes Research Center, Department of Medicine, Hadassah Hebrew University Hospital, Jerusalem 91120, Israel
Rev Diabet Stud 6:6-12. 2009
..Using our newly suggested system, a physician will first calculate the adequate HbA1c goal for his patient and then choose the drug that will best suit him, thus tailoring the treatment to the patients needs...
